Meeder Asset Management Inc Eiger Bio Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$5.4 - $13.37 $8,780 - $21,739	-1,626 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $3,721 - $11,142	758 Added 87.33%	1,626 $11,000
Q4 2019 Feb 13, 2020	BUY	$9.77 - $15.66 $2,559 - $4,102	262 Added 43.23%	868 $13,000
Q1 2019 Apr 16, 2019	SELL	$10.31 - $14.38 $3,134 - $4,371	-304 Reduced 33.41%	606 $8,000
Q3 2018 Nov 02, 2018	BUY	$9.6 - $12.9 $6,777 - $9,107	706 Added 346.08%	910 $0

Q2 2018 Jul 24, 2018	SELL	$8.3 - $16.8 $2,282 - $4,620	-275 Reduced 57.41%	204 $0
Q1 2018 May 03, 2018	SELL	$8.1 - $16.0 $291 - $576	-36 Reduced 6.99%	479 $5,000
Q4 2017 Feb 02, 2018	SELL	$10.5 - $14.15 $1,701 - $2,292	-162 Reduced 23.93%	515 $7,000
Q3 2017 Oct 20, 2017	BUY	$7.7 - $11.55 $5,212 - $7,819	677	677 $7,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $496M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.